Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$110M
Investors
97
Min Invest
$250,000
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp. is a Luxembourg entity that first filed a Form D on August 8, 2022 and most recently amended it on March 2, 2023, describing itself as a other investment fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(7) and covers pooled investment fund interests. Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp. reported $110,065,000 sold from 97 investors in an offering of indefinite size as of the Form D filed March 2, 2023. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $250,000. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. The issuer's address of record is 2, Rue Jean Monnet, Luxembourg, Luxembourg L-2180.
Critical Disclosures
What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.
Reporting lapsed · Form D · last filing March 2, 2023
Offering declared to continue beyond a year; annual amendment 13+ months overdue An issuer that stops filing is the case the going-concern flag cannot catch: the report that would have carried it was never filed.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
dark
Fund family Part of the Healthcare Innovation Fund family: 5 vehicles across 2 generations; Same adviser as J.P. Morgan Access Multi-Strategy Fund II, and 1 other related vehicle · adviser of record Cultivation Capital, LLC · full family and the filing behind each link in the terminal
Investor
- The full fund family and 2 related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Adviser of Record (Form ADV)
CRD 110186 · SEC-registered adviser · lists this fund on Schedule D 7.B.(1) as a private equity fund
Auditor named on Form ADV: Pricewaterhousecoopers, Societe Cooperative · PCAOB-registered per the adviser
From the adviser's Form ADV as loaded from the SEC bulk data, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Healthcare Innovation IV GP S.a r.l.
Executive Officer · Luxembourg, N4
General Partner of Issuer
J.P. Morgan Private Investments Inc.
Executive Officer, Promoter · New York, NY
Portfolio Manager of Issuer
Waystone Management Company (Lux) S.A.
Executive Officer · Luxembourg, N4
Alternative Investment Fund Manager of Issuer
Martin Vogel
Director · Luxembourg, N4
Member of the Board of Managers of the General Partner of the Issuer
Darren Gorman
Director · Luxembourg, N4
Member of the Board of Managers of the General Partner of the Issuer
Catherine Crowley
Director · New York, NY
Member of the Board of Managers of the General Partner of the Issuer
Questions About Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp.?
Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp. is a Luxembourg entity that filed a Form D with the SEC on March 2, 2023 as a other investment fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of pooled investment fund interests.
Is Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp. legit?
AltStreet does not rate legitimacy; it reports the public record. Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp. filed a Form D with the SEC on March 2, 2023 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $110,065,000 sold to 97 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp. claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp. raised?
Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp. reported $110,065,000 sold from 97 investors in an offering of indefinite size as of the Form D filed March 2, 2023.
Who can invest in Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $250,000.
What is the minimum investment in Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp.?
The Form D lists $250,000 as the minimum investment accepted from any outside investor as of March 2, 2023. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp. and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.
Who is behind Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp.?
The Form D lists 6 related persons: Healthcare Innovation IV GP S.a r.l., executive officer (General Partner of Issuer); J.P. Morgan Private Investments Inc., executive officer, promoter (Portfolio Manager of Issuer); Waystone Management Company (Lux) S.A., executive officer (Alternative Investment Fund Manager of Issuer); Martin Vogel, director (Member of the Board of Managers of the General Partner of the Issuer); Darren Gorman, director (Member of the Board of Managers of the General Partner of the Issuer); Catherine Crowley, director (Member of the Board of Managers of the General Partner of the Issuer). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp. located?
The issuer's address on its SEC filings is 2, Rue Jean Monnet, Luxembourg, Luxembourg L-2180. Its phone number of record is 352 44 66 44 5222. It is organized under the laws of Luxembourg.
How long is the Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp. offering open?
The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 4 amendments are on record for this CIK.
How large is Healthcare Innovation Fund IV Offshore SICAV-RAIF S.C.Sp.?
The issuer declined to disclose its net asset value range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.